1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000068525, EORTC-GU-30986, NCT00014274
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CHNT-GEM, EU-20062, NCT00022009
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40013-22012, EORTC-40013, EORTC-22012, FFCD-0304, EU-20540, NCT00064207
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SGI-RUB-048, NCT00113256
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA183-002, NCT00389155
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.09, NCT00415818
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CONKO 004, CCT-NAPN-16752, NCT00785421
|
|
9.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000641309, PACT-7, SRSI-PACT-7, EU-20932, NCT00960284
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/128, NCI-V96-0908
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALFACELL-P30-303, NCI-V96-0938
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1594, E1594
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: MRC-LU22, EORTC-08012, EU-97016, ISRCTN25582437, NCT00003159
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9704, E-R9704, SWOG-R9704, NCT00003216, RTOG-97-04
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-2297, E2297
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-PA1, BAYER-STR-CO2, PA1
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 70 and over
Sponsor:
Protocol IDs: ITA-MILES, ITA-GOCSI-MILES, EU-98019, NCT00003447
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-08975, NCT00003589
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 70
Sponsor: Other
Protocol IDs: ITA-GEMVIN, CAN-NCIC-BR14, EU-99016, NCT00004100, BR14
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PD-994-013, CDR0000067735, ILEX-994-013, NCT00005093
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUPERGEN-RFS2000-02, NCT00005869
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUPERGEN-RFS2000-09, RPCI-DS-99-11, NCT00005870
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000067993, AGOSG-OVAR-2.5, CAN-NCIC-OV15, EORTC-55005, EU-20064, NCI-V00-1601, OV15, NCT00006453
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ZENECA-1839IL/0014, NCT00006048
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2017, LILLY-B9E-MC-JHQG, CDR0000068216, NCT00006459
|
Mobile | Español
